Current Treatments in Mantle Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Mantle cell lymphoma (MCL) historically presents a poor prognosis among non-Hodgkin lymphomas.
• Disease biology and molecular pathogenesis understanding are crucial for improving MCL outcomes.
• High-risk mutations aid in prognostication and risk-adapted treatment strategies for MCL.

Purpose of the Study:

• To provide an overview of molecular mutations identified in MCL.
• To review the evolving treatment strategies for Mantle cell lymphoma.
• To highlight advancements in MCL prognostication and therapeutic approaches.

Main Methods:

• Review of molecular mutations in Mantle cell lymphoma.
• Analysis of current and emerging treatment strategies for MCL.
• Synthesis of data on novel agents and cell-based therapies in MCL treatment.

Main Results:

• Identification of key molecular mutations influencing MCL prognosis.
• Chemoimmunotherapy remains a frontline treatment for MCL.
• Novel agents (BTK inhibitors, BCL-2 inhibitors, immunomodulatory drugs), CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates show promising results in clinical investigations for MCL.

Conclusions:

• Advances in understanding MCL biology and molecular pathogenesis are improving patient outcomes.
• Risk-adapted treatment approaches, guided by mutation identification, are essential for MCL management.
• Emerging therapies, including targeted agents and immunotherapies, represent a new frontier in treating Mantle cell lymphoma.